Skip to main content

Table 1 Breast cancer patient characteristics

From: CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

   Patients WITH self-reported tamoxifen treatment n= 3155 Patients WITHOUT self-reported tamoxifen treatment n= 3485
Median age   53 53
Age range   24-69 23-69
Tumour size group (cm) *N/A 913 (13.8%) 1,275 (19.2%)
  < 2 1,448 (21.8%) 1,380 (20.8%)
  2-5 710 (10.7%) 751 (11.3%)
  5+ 84 (1.3%) 79 (1.2%)
Grade 1 670 (10.1%) 599 (9%)
  2 1,487 (22.4%) 1,318 (19.8%)
  3 560 (8.4%) 1,019 (15.3%)
  *N/A 438 (6.6%) 549 (8.3%)
Positive nodes 0 1,606 (24.2%) 1,476 (22.2%)
  1-3 603 (9.1%) 591 (8.9%)
  4-9 140 (2.1%) 200 (3%)
  10+ 57 (0.9%) 78 (1.2%)
  *N/A 749 (11.3%) 1,140 (17.2%)
Stage 1 1,624 (24.5%) 1,655 (24.9%)
  2 1,359 (20.5%) 1,505 (22.7%)
  3 99 (1.5%) 146 (2.2%)
  4 28 (0.4%) 50 (0.8%)
  *N/A 45 (0.7%) 129 (1.9%)
ER *N/A 959 (14.4%) 1,117 (16.8%)
(oestrogen receptor status) Negative 207 (3%) 668 (10.1%)
  Positive 1,989 (30%) §1,699 (25.6%)
Surgery Yes 1,982 (29.8%) 1,860 (28%)
  No 132 (2%) 220 (3.3%)
  *N/A 1,041 (15.7%) 1,405 (21.2%)
Chemotherapy Yes 587 (8.8%) 782 (11.8%)
  No 1,527 (23%) 1,298 (19.5%)
  *N/A 1,041 (15.7%) 1,405 (21.2%)
Person years follow-up   18,860.38 19,189.94
a Number of events   312 418
  1. *N/A - Data not available.
  2. §Of 1,699 patients, 1,119 (16.9%) patients received hormone treatment but did not document which type; 3 (0.05%) had combined tamoxifen and aromatase treatment; 232 (3.5%) received aromatase; 341(5.1%) received no hormone treatment; 4 (0.06%) patients had no data available.
  3. †Some patients in this group stated that they received adjuvant hormone treatment but did not document which drug.
  4. ‡Percentages given are from total of 6,640.
  5. aBreast cancer specific deaths.